29 results about "Biomarker Analysis" patented technology

The invention discloses a biomarker for nephrotic syndrome, an analysis method and a kit, which can be effectively used for diagnosis of nephrotic syndrome and have high sensitivity and accurate and reliable results. The biomarker for nephrotic syndrome comprises the mRNA, the protein and the enzymatic activity level of the following substances: lactate dehydrogenase B.

We provide specimen analyzers, specimen analysis systems, specimen analysis methods, and programs that can contribute to highly accurate dementia diagnosis using dementia biomarkers. [Solution] The specimen analyzer 1 comprises a measuring device 2 that measures analytes related to dementia biomarkers contained in a specimen taken from a subject, a storage unit that stores reference values ​​for identifying outliers that may occur due to factors other than dementia, a control unit that determines whether the measured value is identified as an outlier based on the measured value of the analyte by the measuring device 2 and the reference value, and generates biomarker analysis results according to the result of the determination, and an output unit that outputs the biomarker analysis results.

The invention relates to the technical field of medical care, and discloses a heart failure patient noninvasive liquid management nursing system which comprises a data acquisition module used for acquiring biomarkers of a heart failure patient and analyzing a body fluid state change rule of the heart failure patient; the body fluid state monitoring module is used for measuring impedance values of different parts of the heart failure patient and analyzing the evolution trend of the retention condition of the liquid retention part; the risk state identification module is used for analyzing the heart failure severity of the heart failure patient; the risk control module is used for generating illness condition guidance suggestions of the heart failure patient, constructing a risk early warning mechanism of the heart failure patient and creating a health management system of the heart failure patient; and the liquid management module is used for analyzing the liquid management effect of the heart failure patient in combination with a health management system, illness condition guidance suggestions and a risk early warning mechanism so as to execute liquid management processing of the heart failure patient and obtain a liquid management result. The pertinence and effectiveness of liquid management nursing of the heart failure patient can be improved.

The invention provides an S100B and NSE double-signal electrochemical immunosensor, a preparation method, application and a detection product, and belongs to the technical field of electrochemical detection. According to the preparation method, the PAMAM dendritic polymer rich in amine-terminated functional groups is covalently grafted to the MXene conductive sheet layer with a large surface area to prepare the PAMAM-MXene composite material, so that the immobilization efficiency and interface electron transfer of immune molecules are remarkably improved through modification, and enhanced conductivity and relatively high specific surface area are shown; and the biomolecule loading capacity and the signal transmission efficiency of the electrode are also remarkably improved, and double-signal detection can be performed on S100B and NSE at the same time. And the electrochemical immunosensor has good reproducibility, long-term stability and anti-interference capability on the two biomarkers. According to the sensor, modular design and signal decoupling are adopted, double targets can be accurately detected in parallel, and an extensible strategy is provided for multiplexing biomarker analysis.

A device (1) whose body (2) due to its convex design (5) makes it anatomical with the palm of the hand of the target individual, who will place it on a collection adapter (10) with medium-sized hollow (12), conducive to the concentration of blood without interrupting the blood flow, which will be submitted for analysis of biomarkers performed in the chamber (9) of the optical system inside the body (2).

A wearable smart ring includes an annular body sized to receive a finger, photoplethysmography (PPG) sensors arranged along an inner peripheral surface, and a microfluidic perspiration collector disposed at the inner surface. The collector has microchannels that draw perspiration by capillary action into one or more reservoirs and includes a region that concentrates or retains biomarkers. A docking station mechanically receives the ring for charging and interfaces with the collector to transfer fluid and / or perform in-situ analysis. The dock includes optical instrumentation (e.g., photometry, spectroscopy such as Raman) and may implement pumping and flushing to reset the collector for subsequent use. A controller communicates results by wireless links. The system enables passive collection of perspiration during wear and detailed biomarker analysis during charging, thereby augmenting PPG-derived physiological measurements with perspiration chemistry without burdening ring power or size.

Provided herein are methods and systems for detection and monitoring of cancer. The method may comprise use of multiple biomarkers, such as fragmentomics, methylation, and gene expression, or transcription factor activation. The methods and systems may comprise using nucleic acids to generate a fragmentomics profile (e.g., nucleosome profile). The methods and systems may comprise assaying nucleic acids to detect expression of genes of a subject.

Immunohistochemistry (INC) and in situ hybridization (ISH) methods are used for the targeted detection and localization of biomolecules (e.g., proteins and miRNAs) in tissues or cells, for research applications and clinical applications such as those of pathologists (e.g., biomarker analysis of resected tumors or tumor biopsies). These methods include mass spectrometry imaging (MSI) as a mode for detecting and localizing biomolecules in tissues or cells. The methods employ optically cleavable mass-tagged reagents linked to probes such as antibodies and nucleic acids and used to enable multiplexed immunohistochemistry and in situ hybridization, with MSI as the detection / readout mode. The methods also include multi-omics MSI procedures in which MSI of optically cleavable mass-tagged probes is combined with other MSI modes, such as direct label-free MSI of endogenous biomolecules from biological samples (e.g., tissues).

Disclosed are miniaturized electronic systems, devices and methods for biomarker analysis, which can be incorporated into blood collection tubes and other containers that enable the immediate isolation, concentration, analysis and storage of disease related biomarkers upon blood draw. In some aspects, a miniaturized electronic system includes a high-surface area folded or sandwiched electrokinetic microelectrode array chip device that allows both AC dielectrophoretic (DEP) and DC electrophoretic based separation and isolation and other processes to be used for the concentration and biomarkers.

Disclosed are novel RNA and protein expression panels and methods of using said panels for the detection of cancer and determining the suitability of a subject for a treatment regimen or clinical trial.

A tape (170) comprising: a base membrane (410) on which dry rods (180a, 180b, 180c) are separately arranged, the dry rods (180a, 180b, 180c) being configured to indicate at least one biomarker value of a milk sample of an animal (100); and a top film (310) configured to cover the plurality of stem rods (180a, 180b, 180c) disposed on the base film (410) and to peel from individual stem rods (180a, 180b, 180c) prior to applying a milk sample to the stem rods (180a, 180b, 180c).

The invention discloses a method for detecting a soil microbial marker-amino sugar by direct ion chromatography, and relates to the technical field of biomarker analysis, and the method comprises the following steps: adding a soil sample into a 6mol / L hydrochloric acid solution, and hydrolyzing at 105 DEG C for 8 hours; drying the hydrolysate with nitrogen, redissolving with ultrapure water, centrifuging, taking supernate, and filtering with a 0.22 mu m filter membrane to obtain a to-be-detected solution; the method comprises the following steps: injecting a to-be-detected solution into an ion chromatography system provided with an electrochemical detector, and carrying out gradient elution by adopting an anion exchange chromatographic column and taking a mixed solution of sodium hydroxide and sodium acetate as a mobile phase to realize separation and quantitative detection of glucosamine (GlcN), galactosamine (GalN), aminomannose (ManN) and muramic acid (Mur). A highly toxic derivatization step necessary for a traditional method is omitted, a sample can be directly injected through three-step purification after acid hydrolysis, and efficient separation of four amino sugars is realized by matching with a special ion chromatography system.

The invention discloses a carrier for acquiring life information and a method for applying the carrier, and belongs to the technical field of biomedicine. The method solves the problem that a required sample is difficult to quickly obtain during practical application of an existing method, realizes accurate extraction and detection of a life information carrier by integrating a magnetic bead separation technology and fluorescent quantitative detection, and performs intelligent classified storage and dynamic management based on data volume and data type, so that the life information carrier can be accurately extracted and detected during practical application. According to the method, quick retrieval and application can be performed in the specified storage area according to the data volume of the life information required to be applied, so that the management efficiency and retrieval speed of the life information are remarkably improved; the system can realize rapid biomarker analysis in disease diagnosis, supports dynamic data tracking in treatment monitoring, promotes accurate scheme formulation in personalized medical treatment, and achieves the comprehensive effects of improving medical detection efficiency, reducing storage cost and enhancing clinical application flexibility.

A non-invasive diagnostic system is disclosed that integrates Raman spectroscopy with Artificial Intelligence (AI) to detect, classify, and quantify biomarkers and pharmacologic agents in the aqueous humor of the anterior chamber of the eye. The system includes a handheld or slit lamp-mounted Raman probe, a spectral acquisition and preprocessing pipeline, and an AI analysis engine trained to recognize disease-associated molecular signatures. The platform supports real-time diagnosis of glaucoma, uveitis, and other anterior segment conditions, enabling early detection, risk stratification, and longitudinal monitoring. The AI component is capable of incorporating newly discovered biomarkers and contextual factors such as medication use, diurnal variation, and anatomical sampling location. Diagnostic outputs are presented with confidence scores and may include disease classification, biomarker trends, or pharmacologic exposure levels. Built-in safety protocols ensure ANSI Z136.1-compliant laser use, while explainable AI tools and federated learning enhance transparency and clinical adaptability.

Systems and methods are provided for improving skincare product formulations to address predicted skin trends. A biomarker analysis system is used to determine concentrations of various protein biomarkers of a user. A skin diagnosis computing device uses the protein biomarker concentrations to determine one or more skin trends, and determines one or more skincare product ingredients to address the skin trends. A skincare product is compounded that includes the one or more skincare product ingredients.

The invention relates to the technical field of tumor cell drug resistance detection, and discloses a construction method and application of a tumor cell drug resistance level detection model based on surface enhanced Raman scattering. The invention particularly provides a tumor cell drug resistance level detection method based on surface enhanced Raman scattering and machine learning (recursive feature elimination-radial basis function-support vector machine), the mixing ratio of silver nanoparticles (70-80 nm, 9-10 mM) enhanced substrate to cell homogenate (1: 2-1: 4) is optimized, Raman spectrum feature extraction and nonlinear modeling are combined, and the drug resistance level of tumor cells is detected. The accurate quantitative detection of the drug resistance index (1-15 times) is quickly realized. Compared with traditional drug sensitive experiments and biomarker analysis, the method has the advantages of high efficiency, high sensitivity, strong anti-interference performance and the like, effectively solves the clinical problems of long period, complex operation and incapability of dynamically monitoring the drug resistance level in the prior art, and provides an efficient and reliable detection tool for personalized treatment of tumors.

Systems, devices, and methods for skin biomarker analysis and computation of predicted responsiveness to skincare treatments for management of skin health. A system is configured to receive a measurement of one or more skin biomarkers, compute a predicted beauty outcome that is predicted to occur due to a course of action, and recommend or not recommend the course of action, based on the responsiveness metric, such that the skin health of the individual is advanced toward a desired beauty outcome. Systems can recommend products, services, and other courses of action such as lifestyle changes, to improve the health of the individual.

The field of this invention relates to immunohistochemistry (IHC) and in situ hybridization (ISH) for the targeted detection and mapping of biomolecules (e.g., proteins and miRNAs) in tissues or cells for example, for research use and for clinical use such by pathologists (e.g., biomarker analyses of a resected tumor or tumor biopsy). In particular, the use of mass spectrometric imaging (MSI) as a mode to detect and map the biomolecules in tissues or cells for example. More specifically, the field of this invention relates to photocleavable mass-tag reagents which are attached to probes such as antibodies and nucleic acids and used to achieve multiplex immunohistochemistry and in situ hybridization, with MSI as the mode of detection / readout. Probe types other than antibodies and nucleic acids are also covered in the field of invention, including but not limited to carbohydrate-binding proteins (e.g., lectins), receptors and ligands. Finally, the field of the invention also encompasses multi-omic MSI procedures, where MSI of photocleavable mass-tag probes is combined with other modes of MSI, such as direct label-free MSI of endogenous biomolecules from the biospecimen (e.g., tissue), whereby said biomolecules can be intact or digested (e.g., chemically digested or by enzyme).

The invention discloses a biomarker composition and application thereof, and belongs to the field of biomarker analysis and detection. The invention firstly provides a group of biomarker compositions, wherein the biomarker compositions comprise a Klotho protein and a neutrophil gelatinase associated lipocalin (NGAL); the combined detection biomarker composition can be used for early assessment of the risk of hypertensive disorder in pregnancy complicated with acute kidney injury. When the marker composition is used for predicting the risk of hypertensive disorder in pregnancy complicated with acute kidney injury, the risk of acute kidney injury can be recognized in advance in the early pregnancy stage.

This disclosure relates generally to the use of automated platforms in the preparation of biomarker-stained cellular samples for microscopic analysis and use of such stained cells in the diagnosis of certain conditions. Disclosed herein is a method of affinity staining a Romanowsky-type stained sample on automated advanced staining systems, wherein the automated advanced stainer destains the sample prior to contact with a biomarker-specific reagent. Also disclosed herein are methods of processing body fluid samples for morphological and biomarker analysis by depositing cells of the sample in a thin layer onto one or more solid supports, staining at least one such solid support with a Romanowsky-type stain and staining at least one such solid support for one or more biomarkers useful for categorizing one or more cells of the sample.

Provided herein are devices, systems, kits and methods for predicting or determining the gender of a fetus using cell free fetal nucleic acids in a small amount of maternal biological sample. Devices can be used at point of need during early stages of pregnancy and are compatible with communication devices.

The field of this invention relates to immunohistochemistry (IHC), immunocytochemistry and in situ hybridization (ISH) for the targeted detection and mapping of biomolecules (e.g., proteins, glycans and RNAs) in tissues or cells for example, for research use and for clinical use such by pathologists (e.g., biomarker analyses of a resected tumor or tumor biopsy). In particular, the use of mass spectrometric imaging (MSI) as a mode to detect and map the biomolecules in tissues or cells for example. More specifically, the field of this invention relates to photocleavable mass-tag reagents which are attached to Probes such as antibodies and nucleic acids and used to achieve multiplex immunohistochemistry, immunocytochemistry and in situ hybridization, with mass spectrometry (MS) and mass spectrometry imaging (MSI) as the mode of detection / readout.

The invention provides a biological micro-fluidic chip device and a detection system contained in the biological micro-fluidic chip device, which can distinguish non-motor bacteria, swimming bacteria or cluster bacteria, and can be further applied to disease diagnosis, biomarkers, target bacteria screening, drug-resistant bacteria screening and cluster inhibitor screening according to detection results. The detection and separation method provided by the invention is proved to be convenient and very valuable, and can further assist diagnosis and treatment. The whole device is relatively miniaturized and portable, and detection can be carried out at any time.

This application relates to the field of biological tissue engineering technology and discloses a scoring method for the likelihood of tumor immune response based on dual-panel multiple biomarker analysis, comprising: staining multiple cells in a tumor tissue section with multiple affinity histochemical stains; obtaining a first and / or second eigenvalue group of cells in a target analysis area defined in a digital image; determining the immunophenotyping of the tumor tissue sample based on at least part of the second eigenvalues ​​in the inner and outer regions of the tumor boundary; obtaining multiple first eigenvalues ​​of the first eigenvalue group within the inner region of the tumor boundary of a tumor tissue sample determined by immunophenotyping as either immune infiltration or immune rejection, scoring each of the multiple eigenvalues, and summing the multiple scores to obtain a score. This scoring method uses 11 cell types as biomarkers to score immune responses to predict the likelihood of tumor patients responding to immunotherapy, and has wide adaptability and strong feasibility.

The invention discloses an athlete dietary nutrition investigation method. The method comprises the following steps: firstly, collecting basic information of participants; blood samples of the participants are collected for subsequent biomarker analysis; after collecting the blood sample, the participants complete a first FFQ for evaluating their dietary habits; after the first-time FFQ, the participant records weighed food for three days, including two workdays and one weekend day, for evaluating the effectiveness of the first-time FFQ; the method comprises the following steps: analyzing biomarkers in a blood sample and food intake of three-day weighing, and comparing the biomarkers and the food intake with the result of the first FFQ to evaluate the effectiveness of the first FFQ; after the first FFQ is completed for one month, the participant completes the second FFQ again so as to evaluate the repeatability of the FFQ; and evaluating the consistency of the questionnaire at different time points by comparing the results of the first FFQ and the second FFQ.

This application provides a system, method, media, program product, and terminal for vascular biomarker analysis and disease diagnosis based on ultrasound-guided microscopy. This application utilizes a unified and optimized ULM (Ultra-Large-Scale Microscopy) workflow to reconstruct complex vascular networks with high precision and resolution. It enables longitudinal imaging of the same observation area, accurately quantifying multidimensional biomarkers and monitoring their changes over time, making it suitable for monitoring disease progression or treatment response. By identifying disease-specific multidimensional biomarkers, this application has successfully differentiated between benign and malignant diseases in clinical trials. This application can be seamlessly integrated into existing clinical ultrasound equipment workflows, enabling microvascular imaging, biomarker extraction, and analysis. The standardized operating procedures and automated analysis significantly lower the technical barrier to entry, assisting scientists and physicians in disease diagnosis and possessing direct potential for clinical application.

The present disclosure relates to methods, systems and kits for the diagnosis, prognosis and the determination of cancer progression of cancer in a subject. The disclosure also provides biomarkers that define subgroups of prostate cancer, clinically useful classifiers for distinguishing prostate cancer subtypes, bioinformatic methods for determining clinically useful subtyping classifiers, and methods of use of each of the foregoing. The methods, systems and kits can provide expression-based analysis of biomarkers for purposes of subtyping prostate cancer in a subject. Further disclosed herein, in certain instances, are probe sets for use in subtyping prostate cancer in a subject. Classifiers for subtyping a prostate cancer are provided. Methods of treating cancer based on molecular subtyping are also provided.

The invention belongs to the field of medical detection, and discloses a nucleic acid aptamer for recognizing sarcosine and application of the nucleic acid aptamer. The aptamer is obtained by constructing an ssDNA initial library containing fixed primers at the two ends and 36 random basic groups in the middle, repeated incubation and screening are conducted through positive screening magnetic beads and negative screening magnetic beads, the positive screening magnetic beads are formed by coupling carboxyl functionalized magnetic beads with sarcosine, and the negative screening magnetic beads are formed by coupling carboxyl functionalized magnetic beads with glycine and alanine. Based on the nucleic acid aptamer, the invention also provides a nucleic acid aptamer-magnetic bead chemiluminescence kit, the kit comprises a reagent 1 and a reagent 2, the reagent 1 comprises a streptavidin magnetic bead coupled nucleic acid aptamer, and the reagent 2 comprises an acridinium ester labeled nucleic acid aptamer. The nucleic acid aptamer is high in stability and specificity, the detection method is easy and convenient to operate, the cost is low, detection is rapid, the nucleic acid aptamer is suitable for efficient detection of sarcosine in complex biological samples, and the nucleic acid aptamer has important application value in the fields of disease diagnosis and biomarker analysis.

The field of this invention relates to immunohistochemistry (IHC) and in situ hybridization (ISH) for the targeted detection and mapping of biomolecules (e.g., proteins and miRNAs) in tissues or cells for example, for research use and for clinical use such by pathologists (e.g., biomarker analyses of a resected tumor or tumor biopsy). In particular, the use of mass spectrometric imaging (MSI) as a mode to detect and map the biomolecules in tissues or cells for example. More specifically, the field of this invention relates to photocleavable mass-tag reagents which are attached to probes such as antibodies and nucleic acids and used to achieve multiplex immunohistochemistry and in situ hybridization, with MSI as the mode of detection / readout. Probe types other than antibodies and nucleic acids are also covered in the field of invention, including but not limited to carbohydrate-binding proteins (e.g., lectins), receptors and ligands. Finally, the field of the invention also encompasses multi-omic MSI procedures, where MSI of photocleavable mass-tag probes is combined with other modes of MSI, such as direct label-free MSI of endogenous biomolecules from the biospecimen (e.g., tissue), whereby said biomolecules can be intact or digested (e.g., chemically digested or by enzyme).